XNAS · Healthcare · Biotechnology
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.11 | -0.13 | -18.18% | $0 | ❌ Miss | -6.13% | -7.34% | — |
| 2026-05-06 | Q1 2026 | -0.10 | -0.12 | -20.00% | $0 | ❌ Miss | +0.14% | -4.44% | -21.20% |
| 2026-03-19 |
| Q4 2025 |
| -0.10 |
| -0.12 |
| -20.00% |
| $5.5M |
| ❌ Miss |
| +2.92% |
| -5.26% |
| +41.01% |
| 2025-11-04 | Q3 2025 | -0.09 | -0.09 | +0.00% | $0 | ➖ Inline | — | — | — |
| 2025-08-12 | Q2 2025 | -0.07 | -0.09 | -28.57% | $2.0M | ❌ Miss | +0.00% | -2.41% | +11.34% |
| 2025-02-26 | Q4 2024 | -0.08 | -0.07 | +12.50% | $2.0M | ✅ Beat | -1.85% | +4.94% | +19.14% |
| 2024-11-13 | Q3 2024 | -0.09 | -0.10 | -11.11% | $1.8M | ❌ Miss | +2.71% | -9.05% | -6.33% |
| 2024-08-12 | Q2 2024 | -0.17 | -0.09 | +47.06% | $1.1M | ✅ Beat | +11.76% | +9.80% | +13.73% |
Showing last 8 quarters.